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Objectives We sought to investigate the predictive value of the SYNTAX (Synergy Between PCI With Taxus and Cardiac Sur-
gery) score (SS) for risk assessment of 1-year clinical outcomes in patients with non–ST-segment elevation acute
coronary syndromes undergoing percutaneous coronary intervention (PCI).
Background In the SYNTAX trial, the SS was effective in risk-stratifying patients with left main and triple-vessel coronary dis-
ease, the majority of whom had stable ischemic heart disease.
Methods The SS was determined in 2,627 patients with non–ST-segment elevation acute coronary syndromes undergoing
PCI in the angiographic substudy of the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY)
trial. Patients were stratified according to tertiles of the SS: 7 (n  854), 7 and 13 (n  825), and 13
(n  948).
Results Among patients in the first, second, and third SS tertiles, the 1-year rates of mortality were 1.5%, 1.6%, and
4.0%, respectively (p  0.0005); the cardiac mortality rates were 0.2%, 0.9%, and 2.7%, respectively (p 
0.0001); the myocardial infarction (MI) rates were 6.3%, 8.3%, and 12.9%, respectively (p  0.0001); and the
target vessel revascularization (TVR) rates were 7.4%, 7.0%, and 9.8%, respectively (p  0.02). By multivariable
analysis, the SS was an independent predictor of 1-year death (hazard ratio [HR]: 1.04, 95% confidence interval
[CI]: 1.01 to 1.07; p  0.005), cardiac death (HR: 1.06, 95% CI: 1.03 to 1.09; p  0.0002), MI (HR: 1.03, 95%
CI: 1.02 to 1.05; p  0.0001), and TVR (HR: 1.03, 95% CI: 1.02 to 1.05; p  0.0001). The SS affected death,
cardiac death, and MI both within the first 30 days after PCI and between 30 days and 1 year, whereas it af-
fected TVR primarily within the first 30 days. The predictive value of an increased SS was consistent among mul-
tiple pre-specified subgroups.
Conclusions In patients with non–ST-segment elevation acute coronary syndromes undergoing PCI, the SS is an independent
predictor of the 1-year rates of death, cardiac death, MI, and TVR. (Comparison of Angiomax Versus Heparin in
Acute Coronary Syndromes [ACS]; NCT00093158) (J Am Coll Cardiol 2011;57:2389–97) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.032Prospectively developed for the SYNTAX (Synergy Be-
tween PCI With Taxus and Cardiac Surgery) trial, the
SYNTAX score (SS) is an angiographic scoring system to
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assessment of the coronary vas-
culature (3). Subsequent reports
have demonstrated that the SS
may be an effective tool for pre-
dicting the risk of major ischemic
events in patients undergoing
percutaneous coronary interven-
tion (PCI) with stable ischemic
heart disease and multivessel or
left main disease (3–10).
Patients with non–ST-segment
elevation acute coronary syn-
dromes (NSTEACS) may have
significant morbidity and mortal-
ity, even with an early invasive
management strategy. Prospec-
tive risk stratification is essential
to estimate patient prognosis, to
aid in clinical decision making,
and to ensure quality control.
Indeed, although clinical predic-
tors of ischemic outcomes in pa-
tients with NSTEACS have
been previously reported (11–15), the role of angiographic
variables is less well defined. In this context, no previous
study has assessed the prognostic utility of the SS in patients
with NSTEACS undergoing PCI. We therefore sought to
investigate the impact of the SS on ischemic outcomes in
patients with NSTEACS undergoing PCI from the multi-
center, prospective randomized ACUITY (Acute Catheter-
ization and Urgent Intervention Triage StrategY) trial.
Methods
Study protocol. The ACUITY trial design was previously
reported in detail (16). Briefly, the ACUITY trial was a
multicenter, prospective, randomized trial of patients with
moderate and high-risk NSTEACS who were managed
with an early invasive strategy. Patients were randomly
assigned before coronary angiography to heparin (unfrac-
tionated or low molecular weight) plus a glycoprotein
IIb/IIIa inhibitor, bivalirudin plus a glycoprotein IIb/IIIa
inhibitor, or bivalirudin monotherapy with provisional gly-
coprotein IIb/IIIa inhibitor use. Angiography was per-
formed in all patients within 72 h of randomization.
Depending on coronary anatomy, patients were then treated
with PCI, coronary artery bypass graft (CABG) surgery, or
medical therapy. In patients undergoing PCI, the choice of
either bare metal or drug-eluting stents was per operator
discretion. Dual antiplatelet therapy with aspirin and clopi-
dogrel was strongly recommended for at least 1 year. All
major adverse events were adjudicated by an independent
clinical events committee blinded to treatment assignment.
Objectives, patients, and angiographic analysis. The pri-
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
CI  confidence interval
HR  hazard ratio
LVEF  left ventricular
ejection fraction








SS  Synergy Between PCI
With Taxus and Cardiac
Surgery score(s)
TIMI  Thrombolysis In
Myocardial Infarction
TVR  target vessel
revascularizationmary objective of the present analysis was to evaluate the simpact of the SS on the risk of individual ischemic out-
comes, including 1-year all-cause death, cardiac death,
myocardial infarction (MI), and target vessel revasculariza-
tion (TVR). We included only the subgroup of PCI
patients in whom quantitative coronary angiography (17)
was performed in the formal angiographic substudy of the
ACUITY trial by experienced core angiographic labora-
tory technicians (Cardiovascular Research Foundation,
New York, New York) blinded to treatment assignment
and clinical outcomes. Because the SS score has been
validated only for patients with native coronary artery
disease, patients with a history of CABG were excluded.
For the present study, the SS for each angiogram was
assessed by 3 experienced interventional cardiologists
blinded to treatment assignment and clinical outcomes.
Each lesion with 50% diameter stenosis in vessels 1.5
mm in diameter was scored using the SS algorithm fully
described elsewhere (1). The Fleiss kappa statistic (18)
(tertile partitioning), determined for the 3 readers from 50
films read independently, was 0.57, signifying interobserver
reproducibility comparable to that previously reported from
the SYNTAX trial (19).
Statistical analysis. Continuous data are presented as
mean  SD and were compared using the Student t test or
he Mann-Whitney rank-sum test, as appropriate. Categor-
cal variables were compared by the chi-square or the Fisher
xact test. Patients were grouped into tertiles of SS. One-
ear outcomes were determined using Kaplan-Meier meth-
dology and compared using the log-rank test. Receiver-
perator characteristic (ROC) curves were also constructed
o assess the predictive accuracy of the SS for 1-year
ll-cause mortality, cardiac mortality, MI, and TVR. The
inimized absolute value of (sensitivity-specificity) was
hosen as the optimal ROC cutoff point. Stepwise Cox
ultivariable regression analyses were performed to assess
he association between the SS and 1-year all-cause mor-
ality, cardiac mortality, MI, and TVR. The following
ariables were included in the models: SS (as a continuous
ariable), age, male sex, white blood cell count, hemoglobin
evels, current cigarette smoking, diabetes, renal dysfunction,
eft ventricular ejection fraction (LVEF), baseline troponin
levation, ST-segment deviation, previous MI, previous PCI,
nd type of stent (drug-eluting vs. bare-metal stent). Land-
ark analyses of all-cause death, cardiac death, MI, and TVR
ere performed using Kaplan-Meier methodology in 2 periods
f interest: from PCI to 30 days and from 31 days to 1 year.
tatistical analyses were performed using SAS version 9.1
SAS Institute, Cary, North Carolina). A p value 0.05 was
onsidered statistically significant.
esults
uantitative coronary angiography was performed in 6,921
atients enrolled in the ACUITY trial angiographic sub-
tudy, including 3,826 patients who underwent PCI. After
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surgery (n  862) and those for whom the SS could not be
calculated due to technical reasons (n 337), 2,627 patients
remained for whom the SS was determined for the present
analysis.
The SS ranged from 0 to 59, with a mean of 11.5  8.4
and median of 9. Clinical and angiographic characteristics
of patients stratified by SS tertiles are shown in Table 1.
Compared with patients in the lower tertile, those in the
upper tertile were older and more likely to have diabetes
mellitus, renal dysfunction, baseline troponin elevation,
ST-segment deviation, higher Thrombolysis In Myocardial
Infarction (TIMI) risk score, and lower LVEF. Patients in
the upper tertile were also more likely to have longer lesions,
bifurcation lesions, thrombus-containing lesions, and heav-
ily calcified lesions than those in the lower 2 tertiles. There
were no significant differences in discharge medication use
of aspirin, clopidogrel, and ticlopidine across SS tertile.
1-year clinical outcomes. At 1-year follow-up, the rates of
all-cause death, cardiac death, MI, and TVR in the overall
cohort were 2.4%, 1.3%, 9.3%, and 8.1%, respectively.
Clinical outcomes stratified according to SS tertiles are
shown in Table 2 and in Figures 1A to 1D. Event rates were
significantly higher in the upper tertile than in the interme-
diate or lower tertiles, whereas no significant difference
existed between the intermediate and lower tertiles. As
shown in Table 3, after adjusting for possible confounders,
the SS was an independent predictor of 1-year all-cause
mortality (hazard ratio [HR]: 1.04, 95% confidence interval
[CI]: 1.01 to 1.07; p  0.005), cardiac mortality (HR: 1.06,
95% CI: 1.03 to 1.09; p  0.0002), MI (HR: 1.03, 95% CI:
1.02 to 1.05; p  0.0001), and TVR (HR: 1.03, 95% CI:
1.02 to 1.05; p  0.0001).
ROC curves and landmark analyses. ROC curve analysis
demonstrated a significant association between the SS and
1-year all-cause mortality, cardiac mortality, MI, and TVR.
As shown in Table 4, the optimal SS cutoff value ranged
from 10 to 13 depending on the outcome considered. The
1-year rates of all-cause death, cardiac death, MI, and TVR
were 4.0%, 2.7%, 12.9%, and 9.8% in patients with an SS
13, respectively, and 1.5%, 0.5%, 7.3%, and 7.2% in those
with an SS 13 (for death, p  0.0001; for cardiac death,
p  0.0001; for MI, p  0.0001; for TVR, p  0.006).
Landmark analyses of clinical outcomes are shown in
Figures 2A to 2D. The rates of death, cardiac death, and MI
were increased in patients with a higher SS, both within the
first 30 days after PCI and between 30 days and 1 year (Figs.
2A to 2C), whereas the rates of TVR were elevated in
patients with a high SS principally within the first 30 days
after PCI (Fig. 2D). As shown in Figure 3, the predictive
value of an increased SS for cardiac death, MI, and TVR
was consistent among multiple pre-specified subgroups,
including the elderly and patients with a low LVEF,
diabetes, renal dysfunction, and positive biomarkers. Therewas no significant interaction between the SS and each of
these patient subgroups.
Discussion
The present study is the first to assess the SS for risk
prediction of ischemic outcomes in patients with
moderate- and high-risk NSTEACS undergoing PCI.
The main findings of this study are the following. 1) The
SS was strongly associated with adverse outcomes after
PCI in NSTEACS; even after adjustment for clinical
variables, the SS was an independent predictor of 1-year
all-cause death, cardiac death, MI, and TVR. 2) Both the
30-day and 1-year rates of death, cardiac death, and MI
were increased in patients with a high SS, whereas an
increased SS was associated with an increased TVR,
primarily within the first 30 days after PCI. 3) The
predictive value of the SS was consistent across numerous
subgroups of patients.
Several studies have identified clinical and laboratory
variables that correlate with a poor prognosis in patients
with NSTEACS. Advanced age (12), clinical presentation
(15), previous aspirin use (11), electrocardiogram performed
at hospital at admission (13), and biochemical evidence of
myocyte necrosis (14) have been consistently reported to be
predictors of reduced survival in this population. The
prognostic role of anatomic and angiographic variables has
been less extensively studied and is unsettled. Recently,
Lansky et al. (20) reported that baseline angiographic
characteristics provide substantial incremental predictive
value for 1-year ischemic outcomes in patients with
NSTEACS treated with PCI, CABG surgery, or medical
therapy (20). In contrast, a recent study from the National
Cardiovascular Data Registry reported that angiographic
factors add little incremental predictive value for in-
hospital mortality after PCI (21). The present large-scale
study demonstrates that the SS is a powerful angio-
graphic predictor in patients with NSTEACS undergo-
ing PCI. The discrepant results between the National
Cardiovascular Data Registry study and the present
analysis may be explained by the fact that the National
Cardiovascular Data Registry study appraised only indi-
vidual angiographic variables, whereas the SS provides a
broad integration of coronary lesion complexity and
atherosclerotic burden. Angiographic factors may yield
relatively little incremental prognostic value when con-
sidered individually, whereas they may provide major
prognostic value when considered additively as an inte-
grated score.
Before the present study, the SS had previously been
associated with the occurrence of major ischemic events,
mostly in stable patients with multivessel and left main
coronary artery disease (3–7,9), but not specifically in
patients with NSTEACS. Recently, the SS was found to
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Tertile I, <7
(n  854)
Tertile II, >7 and <13
(n  825)
Tertile III, >13
(n  948) p Value
Age, yrs 59.3 11.5 (854) 60.0 11.7 (825) 62.6 11.7 (948) 0.0001
Male 63.9% (546/854) 68.0% (561/825) 70.4% (667/948) 0.01
Hypertension 64.5% (572/886) 66.2% (545/823) 66.0% (626/948) 0.72
Diabetes mellitus 25.4% (216/850) 29.6% (243/821) 30.3% (286/943) 0.04
Insulin-treated 7.5% (64/850) 7.8% (64/821) 8.2% (77/943) 0.88
Hypercholesterolemia 56.6% (476/841) 56.2% (458/815) 55.8% (520/932) 0.94
Current smoker 38.2% (325/851) 37.2% (306/823) 31.1% (294/944) 0.003
Previous myocardial infarction 28.3% (237/836) 26.9% (218/809) 31.6% (294/931) 0.09
Previous percutaneous coronary intervention 51.1% (437/853) 42.6% (351/823) 38.8% (367/947) 0.0001
Renal dysfunction 12.4% (99/796) 15.0% (116/774) 18.7% (166/888) 0.002
Left ventricular ejection fraction 56.1 9.8 (671) 54.3 10.6 (645) 50.6 12.7 (767) 0.0001
Baseline troponin elevation 51.3% (368/717) 62.0% (440/710) 67.7% (571/843) 0.0001
ST-segment deviation 1 mm 22.5% (192/854) 24.4% (201/825) 28.9% (263/932) 0.005
TIMI risk score
Low (0–2) 18.0% (122/678) 15.6% (108/691) 15.1% (115/762) 0.29
Intermediate (3–4) 61.2% (415/678) 60.9% (421/691) 55.8% (425/762) 0.06
High (5–7) 20.8% (141/678) 23.4% (162/691) 29.1% (222/762) 0.0008
Antithrombotic medication
Bivalirudin 65.9% (563/854) 66.1% (545/825) 65.1% (617/948) 0.89
Unfractionated heparin 20.8% (178/854) 19.0% (157/825) 19.2% (182/948) 0.58
Enoxaparin 12.8% (109/854) 13.2% (109/825) 13.8% (131/948) 0.80
GPI 65.7% (561/854) 68.8% (568/825) 68.1% (646/948) 0.34
No. of vessel disease 1.3 0.5 (854) 1.5 0.6 (825) 1.9 0.8 (948) 0.0001
Multivessel disease 22.4% (191/854) 40.6% (335/825) 66.9% (634/948) 0.0001
LAD disease 34.4% (294/854) 61.9% (511/825) 75.5% (716/948) 0.0001
Cx disease 38.5% (329/854) 39.2% (323/825) 55.3% (524/948) 0.0001
RCA disease 51.6% (441/854) 46.4% (383/825) 59.4% (563/948) 0.0001
Left main coronary artery disease 0.9% (8/854) 0.6% (5/825) 1.4% (13/948) 0.26
No. of lesions 2.8 1.8 (853) 3.7 2.0 (824) 4.6 2.2 (946) 0.0001
Extent of disease, mm 30.7 20.6 (848) 39.8 26.8 (804) 48.9 28.8 (927) 0.0001
No. of treated vessels 1.1 0.3 (835) 1.2 0.4 (796) 1.3 0.5 (897) 0.0001
Any drug-eluting stent 81.6% (697/854) 87.2% (719/825) 85.9% (814/948) 0.004
Total no. of drug-eluting stents 0.9 0.6 (854) 1.1 0.7 (825) 1.3 0.8 (948) 0.0001
Any bare-metal stent 12.3% (105/854) 13.1% (108/825) 16.5% (156/948) 0.03
Total no. of bare-metal stents 0.1 0.4 (854) 0.1 0.4 (825) 0.2 0.5 (948) 0.006
Lesion length 20 mm 16.1% (159/987) 18.9% (198/1,049) 25.4% (332/1,307) 0.0001
Severe tortuosity 0.4% (4/988) 0.4% (4/1,066) 0.2% (3/1,369) 0.68
Thrombus 10.9% (108/989) 15.4% (164/1,065) 19.0% (260/1,371) 0.0001
Severe calcification 1.8% (17/967) 2.3% (24/1,036) 4.4% (60/1,352) 0.0003
Ulceration 4.1% (40/987) 4.5% (48/1,065) 4.8% (65/1,366) 0.72
Aneurysm 0.8% (8/989) 1.1% (12/1,065) 1.2% (16/1,366) 0.67
Bifurcation present 13.7% (135/988) 23.8% (260/1,094) 23.9% (327/1,367) 0.0001
Baseline QCA
Reference vessel diameter, mm 2.78 0.57 (989) 2.75 0.53 (1,072) 2.72 0.54 (1,376) 0.03
Minimal lumen diameter, mm 0.80 0.47 (989) 0.72 0.46 (1,072) 0.64 0.46 (1,376) 0.0001
Diameter stenosis, % 71.2 15.4 (989) 73.8 15.8 (1,072) 76.0 16.4 (1,376) 0.0001
Final QCA
Reference vessel diameter, mm 2.83 0.56 (984) 2.79 0.53 (1,072) 2.76 0.54 (1,364) 0.01
Minimal lumen diameter, mm 2.40 0.55 (983) 2.33 0.53 (1,072) 2.25 0.58 (1,364) 0.0001
Diameter stenosis, % 15.3 9.7 (983) 16.5 10.6 (1,072) 18.4 13.9 (1,364) 0.0001
Data are mean  SD (N) or % (n/N). Renal dysfunction is defined as a calculated creatinine clearance rate 60 ml/min determined by the Cockcroft-Gault equation.
Cx  circumflex artery; GPI  glycoprotein IIb/IIIa inhibitor; LAD  left anterior descending artery; QCA  quantitative coronary angiography; RCA  right coronary artery; TIMI  Thrombolysis In
Myocardial Infarction.
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in the all-comers population of the LEADERS (Limus
Eluted from A Durable versus Erodable Stent Coating) trial
(22). Distinctive aspects of our study compared with its
predecessors are the higher number of patients enrolled,
Figure 1 Kaplan-Meier Curves Showing Cumulative Event Rates
All-cause mortality (A), cardiac mortality (B), myocardial infarction (C), and target
significantly higher in the upper tertile of SYNTAX score than in the intermediate o
lower tertiles.
1-Year Clinical Outcomes According to SYNTAX Score TertilesTable 2 1-Year Clinical Outcomes According to SYNTAX Score
Tertile I, <7
(n  854)
Tertile II, >7 and <13
(n  825)
Major adverse cardiovascular events 15.9% (127) 16.6% (134)
Death 1.5% (12) 1.6% (13)
Cardiac death 0.2% (2) 0.9% (7)
Myocardial infarction 6.3% (52) 8.3% (67)
Q-wave 1.1% (9) 1.1% (9)
Non–Q-wave 5.2% (43) 7.2% (58)
Death or myocardial infarction 7.3% (61) 9.5% (77)
Target vessel revascularization 7.4% (56) 7.0% (55)
Values are % (n). Major adverse cardiovascular events denotes cardiac mortality, myocardial infawith the ACUITY angiographic substudy representing the
largest quantitative coronary angiography study to date in
any setting; exclusive evaluation of NSTEACS patients
undergoing PCI; appraisal of the SS in the prognosis of
individual ischemic outcomes (rather than just composite
ugh 1 Year
l revascularization (D) stratified by tertiles of SYNTAX score. Event rates were







Tertile I vs. II
p Value for
Tertile II vs. III
p Value for
Tertile I vs. III
.9% (213) 0.0001 0.41 0.0006 0.0001
.0% (37) 0.0005 0.79 0.003 0.001
.7% (25) 0.0001 0.09 0.005 0.0001
.9% (120) 0.0001 0.11 0.002 0.0001
.7% (25) 0.009 0.95 0.02 0.01
.3% (96) 0.0002 0.09 0.02 0.0001
.0% (140) 0.0001 0.11 0.0004 0.0001
.8% (89) 0.02 0.93 0.02 0.02
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lower SS values. Regarding the latter point, although in
earlier studies, the mean SS ranged from 20 to 30 (3–7,9),
in our study, the mean SS was 11. It is noteworthy that
relatively low SS cutoff points in the present study (ranging
from 10 to 13) possessed significant accuracy in predicting
individual adverse ischemic outcomes. As a continuous
variable, the SS was independently associated with 1-year
all-cause death, cardiac death, MI, and TVR. Of note, only
60 patients (2.3%) undergoing PCI in the present study had
an SS of 33, demonstrating the rarity of this practice
outside of the SYNTAX trial.
The rates of all-cause mortality, cardiac mortality, and
MI were increased in the higher SS cohort both within the
first 30 days after PCI and between 30 days and 1 year. The
increased 30-day rates of death and MI in patients with
high SS may be explained by the higher procedural risk
associated with complex lesions. A high SS is also a marker
Independent Predictors of 1-Year Clinical OutcomesTable 3 Independent Predictors of 1-Year Clinical Outcomes
Hazard Ratio (95% CI) p Value
All-cause mortality
SYNTAX score 1.04 (1.01–1.07) 0.005
Age (per 10-yr increments) 2.07 (1.55–2.78) 0.0001
Diabetes 2.41 (1.34–4.31) 0.003
Left ventricular ejection fraction 0.97 (0.95–0.99) 0.02
Current cigarette smoking 2.15 (1.08–4.25) 0.03
Cardiac mortality
SYNTAX score 1.06 (1.03–1.09) 0.0002
Age (per 10-yr increments) 1.76 (1.21–2.54) 0.003
Diabetes 2.47 (1.15–5.28) 0.02
Left ventricular ejection fraction 0.96 (0.94–0.99) 0.006
Current cigarette smoking 2.63 (1.12–6.19) 0.03
Myocardial infarction
SYNTAX score 1.03 (1.02–1.05) 0.0001
Age (per 10-yr increments) 0.85 (0.74–0.97) 0.02
Previous PCI 1.40 (1.04–1.89) 0.03
Renal insufficiency 2.65 (1.85–3.80) 0.0001




SYNTAX score 1.03 (1.02–1.05) 0.0001
Age (per 10-yr increments) 0.81 (0.72–0.92) 0.0007
Renal insufficiency 1.68 (1.18–2.40) 0.004
Previous PCI 1.90 (1.49–2.41) 0.0001
CI  confidence interval; PCI  percutaneous coronary intervention.
Receiver-Operator Characteristic Curve AnalysisAssociation Be ween SYNTAX Score and Indiv dTable 4 R ceiver-Operator Characteristic CuAssociation Between SYNTAX Scor
AUC p Value
All-cause death 0.64 0.0001
Cardiac death 0.72 0.0001
Myocardial infarction 0.61 0.0001
Target vessel revascularization 0.58 0.0001AUC  area under the curve.for diffuse atherosclerosis, which likely contributed to the
worsened late prognosis. Because the SS includes anatomic
variables strongly associated with restenosis (including the
number of lesions, bifurcations, ostial disease, and so on),
we were surprised that higher SS were not associated with
increased rates of TVR after 30 days. This observation is
consistent with some (22) but not all (9,23) previous studies
and thus requires additional investigation. Because in the
ACUITY trial all revascularizations categorized as TVR
were by definition unplanned, staged procedures had no
impact on the 30-day rate of TVR. All studies, however,
have consistently shown an increased rate of TVR within 30
days after PCI in patients with a high SS.
Current risk scores for NSTEACS are based only on
clinical, biochemical, and/or electrocardiographic variables
(11,24). The SS, in contrast, is a pure angiographic measure
of anatomic coronary complexity. These considerations
notwithstanding, the present study demonstrates that the
SS is a powerful independent predictor of adverse ischemic
outcomes during 1-year follow-up in patients with
NSTEACS undergoing PCI, even after adjustment for
clinical variables. The present study thus demonstrates that
in addition to clinical variables, angiographic factors also are
important for risk-stratifying NSTEACS patients undergo-
ing PCI.
Along with the SS, advanced age, diabetes, and re-
duced LVEF were independent predictors of all-cause
and cardiac death, and renal insufficiency was an additive
independent correlate of MI and TVR. Thus, risk scores
incorporating both clinical and angiographic variables
may be more accurate than those including either alone.
In 2 previous studies in different patient cohorts, the
prognostic utility of the SS was improved by integrating
it with the Euroscore (25) or a modified ACEF (age,
creatinine, and ejection fraction) score (23). Whether this
holds true for patients with NSTEACS deserves further
investigation. One advantage of the SS, however, is that
it was created before the SYNTAX trial and then
prospectively validated. The modified (post-hoc) clinical
and angiographic risk scores require prospective valida-
tion and comparison with the SS before they are accepted
into routine clinical practice.
Study limitations. As a retrospective analysis from a pro-
spective, randomized trial, the results should be considered
hypothesis generating. Although we corrected for measured
onstrating thedverse Ischemic Outcomesnaly is Demonstrating the
Individual Adverse Ischemic Outcomes
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founders may still persist.
Choice of stent was not randomized in the ACUITY
trial, and the patient cohort in the present analysis was
drawn from the U.S.-based angiographic substudy in which
a higher proportion of drug-eluting stents was used than in
the entire ACUITY trial. However, multivariable adjust-
ment for selection of drug-eluting stent versus bare metal
stent use did not affect the results. A recent study suggested
that incomplete revascularization may be associated with
worse clinical outcomes in patients with multivessel disease
and high SS undergoing PCI (26). Data on completeness of
revascularization were not systematically collected in the
ACUITY trial, and therefore we could not evaluate the
impact of this variable on 1-year outcomes. Patients who
had undergone previous CABG surgery were not included
because the SS algorithm was developed only for patients
Figure 2 Landmark Analyses
All-cause mortality (A), cardiac mortality (B), myocardial infarction (C), and target
and between 30 days and 1 year in patients with high versus low SYNTAX scores.
patients with a higher SYNTAX score both within the first 30 days after the proced
tions were elevated in patients with a high SYNTAX score principally within the firswith native coronary artery disease. All total occlusions werescored as having unknown duration; many of these occlu-
sions in the ACUITY trial were likely of short duration,
leading to overestimation of the SS. The SS is calculated by
visual lesion assessment, and therefore interobserver vari-
ability may affect its reproducibility (19). Finally, whether
these findings may be extended to NSTEACS patients
treated conservatively or with CABG deserves further in-
vestigation.
Conclusions
In patients with moderate- and high-risk NSTEACS un-
dergoing PCI after an early invasive management strategy,
the SS is an independent predictor of 1-year mortality,
cardiac mortality, MI, and TVR, even after correcting for
clinical variables. As such, the SS may be a useful tool for
l revascularization (D) within 30 days from percutaneous coronary intervention
tes of death, cardiac death, and myocardial infarction were increased in
d between 30 days and 1 year, whereas the rates of target vessel revasculariza-
ays after percutaneous coronary intervention.vesse
The ra
ure an
t 30 drisk stratification in this patient population.
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